SCHEMBL1009291

SCHEMBL1009291

O=c1cc(Oc2c(F)cccc2F)cnn1C1CCCCO1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 6/20 0.43
▸ CYP4A11 Q02928 6/20 0.43
▸ ALDH1A1 P00352 3/20 0.38
▸ LMNA P02545 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ RXRA P19793 1/20 0.36
▸ RXRB P28702 1/20 0.36
▸ RXRG P48443 1/20 0.36
▸ GRIN2B Q13224 1/20 0.35
▸ HRH3 Q9Y5N1 1/20 0.34
▸ TNK2 Q07912 1/20 0.34
▸ ATR Q13535 3/20 0.34
▸ HPGD P15428 1/20 0.33
▸ ESR1 P03372 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ CYP1A2 P05177 1/20 0.32
▸ GLA P06280 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ HIF1A Q16665 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008474 0.79 CYP4F2 (0.36) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL12362928 0.79 ALDH1A1 (0.45) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL8740164 0.78 ALDH1A1 (0.45) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL1366940 0.76 CYP4F2 (0.46) CYP4F2CYP4A11ALDH1A1RXRARXRB
SCHEMBL1366880 0.75 CYP4F2 (0.51) CYP4F2CYP4A11ALDH1A1RXRARXRB
SCHEMBL4046867 0.75 CYP4F2 (0.45) CYP4F2CYP4A11
SCHEMBL158142 0.75 CYP4F2 (0.45) CYP4F2CYP4A11
SCHEMBL3475925 0.74 ALDH1A1 (0.40) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL1366609 0.73 CYP4F2 (0.46) CYP4F2CYP4A11ALDH1A1LMNAPOLB
SCHEMBL30301952 0.72 CYP4F2 (0.46) CYP4F2CYP4A11ALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 — — EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK CYP4F2 299/4885CYP4A11 1439/4885ALDH1A1 1059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback